Contribute to a Research Study for Endometrial Cancer
Did you know that endometrial cancer (EC) is on the rise in the US? Especially, EC that has increased levels of HER2 protein is often thought to be more aggressive and leading to poorer outcomes.
What the study involves:
The investigational AdHER2DC vaccine is created from the blood cells of each participant. The process involves apheresis, where a tube attached to a needle is used to send the blood to a machine that will separate blood cells and return the rest of the blood to the body through a second needle. In some cases, a special catheter may be required for the procedure. The first study drug cycle lasts for 28 days, and subsequent cycles will be 21 days each. The study drugs may continue up to a year.
Who is eligible:
Adults aged 18 and older with HER2-expressing EC that returned or got worse after treatment. Research procedures for participants will be provided at no cost at the NIH Clinical Center. There could be additional reimbursement options for travel and lodging.
The NIH Clinical Center, America's Research Hospital, is located in Bethesda, MD, on the Metro Red Line (Medical Center stop).
For more information:
NIH Clinical Center Office of Patient Recruitment
800-411-1222
TTY users dial 7-1-1
Email: ccopr@nih.gov
Or go online:
https://go.nih.gov/NEJnMuT
Refer to NIH study # 001557-C
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)